Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 1 · 50%High 1 · 50%

Donepezil 10 mg/day vs placebo

Adverse events (all adverse events) at 24 weeks · vascular dementia and other vascular cognitive impairments

Donepezil 10 mg leads to higher adverse events (all adverse events) at 24 weeks compared with placebo (high certainty).

1 finding from 1 review

Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis 2021 · Cochrane Headline outcomes only
OR 1.95 [1.2, 3.15]
2 studies · 813 participants
High

Donepezil 5 mg vs placebo

Adverse events (all reported adverse events grouped) at 24 weeks · vascular dementia and other vascular cognitive impairments

Donepezil 5 mg showed no clear difference in adverse events (all reported adverse events grouped) at 24 weeks compared with placebo (moderate certainty).

1 finding from 1 review

Cholinesterase inhibitors for vascular dementia and other vascular cognitive impairments: a network meta‐analysis 2021 · Cochrane Headline outcomes only
OR 1.22 [0.94, 1.58]
3 studies · 1772 participants
Moderate